Abpro Holdings, Inc.

Abpro Holdings, Inc., trading under the ticker ACAB, filed an S-1 registration statement with the Securities and Exchange Commission on December 23, 2024, under accession number 0001213900-24-111919. The company operates in the biopharmaceutical sector, with a focus on antibody-based therapeutic development. The S-1 filing marks the company's formal step toward a public listing, with the offering subject to SEC review and customary pricing procedures at the time of submission. The filing reflects continued activity in the life sciences segment of the public markets heading into 2025. Investors and analysts seeking full filing details, financial disclosures, and deal timelines for Abpro Holdings and comparable offerings can sign up for complete data access on SpacDesk.